Target intelligence / Profile preview

C-X-C motif chemokine ligand 13 (CXCL13)

Target
CXCL13
Molecular classification
Chemokine, Cytokine, Small secreted protein, CXC chemokine family, Ligand (for chemokine receptor CXCR5)
01

Overview

C-X-C motif chemokine ligand 13 (CXCL13) is a small secreted protein of the CXC chemokine family, acting primarily as a chemoattractant for B cells by binding to the chemokine receptor CXCR5. CXCL13 plays a central role in the formation and organization of lymphoid follicles within secondary lymphoid organs such as lymph nodes, spleen, and Peyer’s patches, guiding B cell migration and positioning. It is essential for normal immune system architecture and function, is highly expressed in specific lymphoid stromal cells, and can also be upregulated in monocyte-like and macrophage lineages under inflammatory conditions. Pathologically, aberrant CXCL13 production contributes to the development of tertiary lymphoid structures in chronic inflammation and is a feature of various autoimmune diseases and certain cancers. CXCL13’s expression is clinically relevant as a biomarker for B cell-driven disease processes and is under investigation as a therapeutic target in immune-mediated and lymphoproliferative disorders.

Other names
B lymphocyte chemoattractantB cell-attracting chemokine 1BCA-1BLCSCYB13BLR1LANGIEANGIE2small-inducible cytokine B13B cell chemoattractantCXC chemokine BLC
02

Mechanism of action

Drugs in research may act as neutralizing antibodies or inhibitors blocking CXCL13-CXCR5 interaction, inhibiting B cell homing and germinal center formation

03

Biological functions

Immune responseB cell chemotaxis (guidance and recruitment)Lymphoid organ development and organizationMaintenance of lymphoid follicle architectureRegulation of B cell position in lymphoid tissues
04

Disease associations

Autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus)Cancer (e.g., lymphoma, prostate cancer, other solid tumors)InflammationInfection (by shaping lymphoid tissue microenvironments)Other (lymphoproliferative disorders, immune-mediated inflammatory diseases)
05

Safety considerations

Targeting CXCL13 may impair normal immune responsesdisrupt lymphoid follicle structure/functionincrease infection riskproduce unintended immunosuppression
06

Interacting drugs

None approved or well-characterized small molecule inhibitors or drugs directly targeting CXCL13 as of 2024; research tools (antibodies, inhibitors) in preclinical/early studies
07

Biomarkers

Elevated serum or CSF CXCL13 levels used as a biomarker for B cell activity, especially in conditions like rheumatoid arthritis, multiple sclerosis, and B cell lymphomas

Beyond the preview

Go deeper on C-X-C motif chemokine ligand 13 (CXCL13).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-X-C motif chemokine ligand 13 (CXCL13).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call